Arvinas Inc (ARVN) Options

ARVN new 52=week high

ARVN new 52 week high

ARVN new 52 week high

ARVN new 52 week high

ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”

Advantages of PROTACs vs. inhibition...

message_id=152832655

Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25

Starting to see a chink in the armor!

Possibly wall at 30.50

I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price

The offering:

8-k

Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!

It doesn't have to be a PR:

#8

Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30

https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/

When did they Do a price target announcement? I didn’t see that.

If I were in this one (I'm not), I'd be finding the exit on the price target announcement.

Arvn looking good, defintely see $26-27

What you mean IBD?

Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...

I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul

Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.

What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60

Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!

Fook R's!

EOM

Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!

ARVN

This stock very volatile, no rhyme or reason why it’s been up and down.

Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/